CGEM Similar Chart Price Prediction
The price of CGEM is predicted to go up -11.98%, based on the high correlation periods with CERS. The similarity of these two price pattern on the periods is 98.01%.
CGEM
CERS
Down: -11.98%Similarity: 98.01%
CGEM Revenue Forecast
CGEM EPS Forecast
CGEM Analyst's Forecast
David Dai
UBS
Strong Buy
2024-10-24
Price Target
$30
Upside
+87.97%
UBS initiated coverage of Cullinan Therapeutics with a Buy rating and $30 price target. The firm launched coverage of SMID cap biotech sector with a focus in oncology and autoimmune diseases. Its top pick is Syndax. Cullinan has an innovative T cell engager "ready to disrupt" the multibillion dollar autoimmune market, the analyst tells investors in a research note.
